Submission & Approval

electronic Common Technical Document(eCTD)

A standardized electronic format for organizing and submitting regulatory applications to health authorities worldwide.

Usage Examples

The FDA requires all NDA and BLA submissions to be in eCTD format.
Our eCTD sequence passed all validation checks before submission.
The sponsor submitted an eCTD amendment to address the deficiency letter.

What is eCTD?

The electronic Common Technical Document (eCTD) is the internationally agreed format for pharmaceutical regulatory submissions. Developed by the International Council for Harmonisation (ICH), eCTD organizes application content into five modules covering administrative information, summaries, quality data, nonclinical studies, and clinical data.

The eCTD format uses XML backbone files to describe the structure and enable lifecycle management of submissions. This allows regulatory agencies to efficiently navigate complex applications and track changes across submission sequences.

Current versions include eCTD v3.2.2 (widely adopted) and eCTD v4.0 (also known as RPS - Regulatory Product Submission), which introduces enhanced lifecycle management capabilities.

Regulatory Context

This term appears most often in submission & approval workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside ICH M8, 21 CFR 11, 21 CFR 314.

FDAICHEMA

When This Matters

The FDA requires all NDA and BLA submissions to be in eCTD format.
Our eCTD sequence passed all validation checks before submission.
The sponsor submitted an eCTD amendment to address the deficiency letter.

Common Mistakes

Treating submission readiness as a formatting-only check without lifecycle validation.
Using outdated guidance references across modules and summaries.
Missing cross-functional review between RA, CMC, and quality before submission.

Related Regulations

ICH M821 CFR 1121 CFR 314

Frequently Asked Questions

eCTD 4.0 (RPS) introduces enhanced lifecycle management, improved metadata handling, and better support for regional requirements. It uses a new XML schema and messaging system compared to the folder-based structure of v3.2.2.

Yes, since May 2017, the FDA requires all NDAs, ANDAs, BLAs, and master files to be submitted in eCTD format. INDs must also use eCTD format.

Module 1: Regional Administrative Information, Module 2: CTD Summaries, Module 3: Quality (CMC), Module 4: Nonclinical Study Reports, Module 5: Clinical Study Reports.